Sun Pharma Launches Ilumya for Plaque Psoriasis in India
Filing Summary
Sun Pharmaceutical Industries Ltd. has announced the introduction of its drug, Ilumya, in India for treating moderate-to-severe plaque psoriasis. Ilumya, a biologic treatment, has been used globally and is now available in India following a clinical study involving 115 patients. The study showed significant skin clearance in patients over a 28-week period. This launch aligns with Sun Pharma’s strategy to expand its innovative drug portfolio in India. The company is a leading player in the pharmaceutical sector, focusing on specialty and generic products.
Sun Pharmaceutical Industries Ltd. has introduced its global drug, Ilumya (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis. This announcement was made on December 1, 2025, and marks the availability of Ilumya in the Indian market. The drug has been recognized by dermatologists in the US and other countries for its efficacy and safety in treating plaque psoriasis.
The financial terms related to the launch of Ilumya in India were not disclosed in the filing. However, the introduction of this drug is part of Sun Pharma’s strategy to enhance its portfolio of innovative medicines in the Indian market. The company has not provided specific revenue projections or financial impacts related to this launch.
Operationally, Ilumya is a biologic treatment that has been endorsed for its effectiveness in achieving significant and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis. The drug was tested in a clinical study in India involving 115 patients, where it demonstrated a 75 percent skin clearance in 62.3% of patients at Week 12, increasing to 93.9% by Week 28. Additionally, a 90 percent skin clearance was observed in 26.3% of patients at Week 12, rising to 78.1% by Week 28. Patients received three subcutaneous injections over 16 weeks and were monitored for 28 weeks.
The timeline for the introduction of Ilumya in India began with the clinical study, which included a follow-up period of 28 weeks. The drug is now available for prescription in India, following its successful trials and regulatory approvals.
Sun Pharmaceutical Industries Ltd., headquartered in Mumbai, India, is the entity responsible for the launch of Ilumya. The company, along with its subsidiaries and associate companies, is involved in the development, manufacturing, and marketing of pharmaceutical products globally. The filing did not mention any other parties involved in the launch of Ilumya in India.
The introduction of Ilumya in India is significant in the context of the country’s healthcare market, where plaque psoriasis affects a notable portion of the population. The prevalence of psoriasis in India ranges from 0.44% to 2.8%. The availability of Ilumya provides a new treatment option for patients who have not achieved adequate disease control with existing therapies. The drug’s long-term efficacy and safety profile make it a viable option for sustained disease management.
Sun Pharmaceutical Industries Ltd. is a leading pharmaceutical company with a strong presence in specialty, generics, and consumer healthcare products. It is the largest pharmaceutical company in India and a major player in the global market. Sun Pharma’s operations span over 100 countries, with a focus on delivering high-quality medicines across various therapeutic areas.